Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (11): 1211-1215.
Previous Articles Next Articles
ZHU Xiao-qin, HONG Hua-shan
Received:
2007-06-19
Revised:
2007-09-10
Published:
2020-11-04
CLC Number:
ZHU Xiao-qin, HONG Hua-shan. Cardioprotective function of brain natriuretic peptide in patients with heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(11): 1211-1215.
Add to citation manager EndNote|Ris|BibTeX
URL: https://manu41.magtech.com.cn/Jweb_clyl/EN/
https://manu41.magtech.com.cn/Jweb_clyl/EN/Y2007/V12/I11/1211
1 Bruneau BG, Piazza LA, de Bold AJ.BNP gene expression is specifically modulated by stretch-and ET-1 in a new model of isolated rat atria[J]. Am J Physiol, 1997; 273:H2678-H2686. 2 Nazario B, Hu RM, Pedram A, et al.Atrial and brain natriuretic peptides stimulate the produc-tion and secretion of C-type natriuretic peptide from bovine aortic endothelial cells[J]. J Clin Invest, 1995;95: 1151-1157. 3 Van der Zander K, Houben AJ, Kroon AA, et al.Nitric oxide and potassium channels are invol-ved in brain natriuretic peptide induced vasodilatation in man[J]. J Hypertens, 2002; 20:493-499. 4 Cataliotti A, Boerrigter G, Chen HH, et al.Differential actions of vasopeptidase inhibition versus angiotensin converting enzyme inhibitionon diuretic therapy in experimental congestive heart failure[J]. Circulation, 2002;105:639-644. 5 Chen HH, Lainchbury JG, Harty GJ, et al.Subcutaneous brain natriuretic peptide and acute vas-opeptidase inhibition maximizing the natriuretic peptide system in experimental heart failure[J]. Circulation, 2002;105:999-1003. 6 Almirez R, Protter AA.Clearance of human brain natriuretic peptide in rabbits; effect of the k-idney, the natriuretic peptide clearance receptor, and peptidase activity[J]. J Pharmacol Exp Ther, 1999; 289:976-980. 7 Yoshimura M, Yasue H, Morita E, et al.Hemodynamic, renal, and hormonal responses to brainnatriuretic peptide infusion in patients with congestive heart failure[J]. Circulation, 1991; 84: 1581-1588. 8 Chen HH, Grantharn JA, Schirger JA, et al.Subcutaneous administration of brain natriuretic peptide in experimental heart failure[J]. JACC, 2000;36: 1706-1712. 9 Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al.Brain natriuretic peptide enhances re-nal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure[J]. Circulation, 2004; 109:1680-1685. 10 Marcus LS, Hart D, Packer M, et al.Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A doubleblind, placebocontrol-led, randomized crossover trial[J]. Circulation, 1996; 94: 3184-3189. 11 Van der Zander K, Houben AJ, Kroon AA, et al.Effects of brain natriuretic peptide on forear-m vasculature: comparison with atrial natriuretic peptide[J]. Cardiovasc Res, 1999;44: 595-600. 12 Protter AA, Wallace AM, Ferraris VA, et al.Relaxant effect of human brain natriuretic peptide on human artery and vein tissue[J]. Am J Hypertens, 1996;9:432-436. 13 Houben AJ, KrekelsM, Schaper NC, et al.Microvascular effects of atrial natriuretic peptide (ANP) in man:studies during high and low salt diet[J]. Cardiovasc Res, 1998; 39: 442-450. 14 Supaporn T, Wennberg PW, Wei CM, et al.Role for the endogenous natriuretic peptide syste-m in the control of basal coronary vascular tone in dogs[J]. Clin Sci(Lond),1996; 90: 357-362. 15 Okumura K, Yasue H, Fujii H Kugiyama, et al.Effects of brain (B-type) natriuretic peptide oncoronary artery diameter and coronary hemodynamic variables in humans:comparison with effects on sy stemic hemodynamic variables[J]. J Am Coll Cardiol, 1995; 25:342-348. 16 Zellner C, Protter AA, Ko E, et al.Coronary vasodilator effects of BNP:mechanisms of action in coronary conductance and resistance arteries[J]. Am J Physiol, 1999; 276:H1049-H1057. 17 Brunner F, Wolkart G.Relaxant effect of c-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature[J]. Cardiovasc Res, 2001; 51: 577-584. 18 Tei M, Horie M, Makita T, et al.Atrial natriuretic peptide reduces the basal level of cytosolic free Ca2+ in guinea pig cardiac myocytes[J]. Biochem Biophys Res Commun, 1990;167:413-418. 19 Lin X, Hanze J, Heese F, et al.Gene expression of natriuretic peptide receptors in myocardial cells[J]. Circ Res, 1995; 77:750-758. 20 Oliver PM, Fox JE, Rockman HA, et al.Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor[J]. A Proc Natl Acad Sci USA, 1997; 94: 14730-14735. 21 Calderone A, Thaik CM, Takahashi N, et al.Nitric oxide, atrialnatriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts[J]. J Clin Invest, 1998;101:812-818. 22 Orio T, Nishikimi T, Yoshihara F, et al.Inhibitory regulation of hypertrophy by endogenous at-rial natriuretic peptide in cultured cardiac myocytes[J]. Hypertension, 2000;35:19-24. 23 Edler B, Lohmann SM, Smolenski A, et al.Inhibition of calcineurin-NFAT hypertrophy signali-ng by cGMP-dependent protein kinase type I incardiacmyocytes[J]. Proc Natl Acad Sci USA, 2002; 99:11363-11368. 24 Bikat A, De Windt LJ, Zetsche B, et al.Local atrial natriuretic peptide signaling prevents hy-pertensive cardiac hypertrophy in endothelial nitricoxide synthase-deficient mice[J]. J Biol Chem, 2005; 280:21594-21599. 25 Ltwick R, van EickelsM, Skryabin BV, et al.Pressure-independent cardiac hypertrophy in micewith cardiomyocyte-restricted inactivation of the atrial natriuretic petide receptor guanylyl cyclase[J]. A J Clin Invest, 2003; 111: 1399-1407. 26 Masato kasahara M, Mukoyama M, Sugawara A, et al.Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation[J]. J Am Soc Nephrol, 2000; 11: 1691-1701. 27 Nishikimi T, Maeda N, Matsuoka H.The role of natriuretic peptides in cardio-protection[J]. Cardiaovasc Res, 2006;69: 318-328. 28 Kapoun AM, Liang F, O Young G, et al.B-type natriuretic peptide exerts broad functional o-pposition to transforming growth factor-beta in primaryhuman cardiac fibroblasts:fibrosis, myofi-broblast conversion, proliferation, and inflammation[J]. Circ Res, 2004; 94:453-461. 29 Yoshimura M, Nakamura S, Nakayama M, et al.Expression of aldosterone synthase gene in fa-iling human heart:quantitative analysis using modified realtime polymerase chain reaction[J]. J Clin EndocrinolMetab, 2002;87: 3936-3940. 30 Kasahara M, Mukoyama M, Sugawara A, et al.Ameliorated glomerular injury in mice overexp-ressing brain natriuretic peptide with renal ablation[J]. J Am Soc Nephrol, 2000;11: 1691-1701. 31 Thomas CJ, Head GA, Woods RL.Similar baroreflex bradycardic actions of atrial natriuretic p-eptide and B and C types of natriuretic peptides in conscious rats[J]. J Hypertens, 1999; 17: 801-806. 32 Thomas CJ, May CN, Sharma AD, et al.ANP, BNP and CNP enhance bradycardic responses to cardiopulmonary chemoreceptor activation in conscious sheep[J]. Am J Physiol Regul Integr Comp Physiol, 2001;280:R282-288. 33 Thomas CJ, Woods RL.Guanylyl-cy clase receptors mediate cardiopulmonary vagal reflex a-ctions of ANP[J]. Hypertension, 2003;41:279-285. 34 Brunner La, Rocca HP, Kaye DM, et al.Effects of intravenous brain natriuretic peptide on reg-ional sympathetic activity in patients with chronic heart failure as compared with healthy controlsubjects[J]. J Am Coll Cardiol, 2001;37:1221-1227. 35 Woods RL.Cardioprotective functions of atrial natriuretic peptide and B-type natriuretic p-eptide a brief review[J]. Clin Exp Pharmacol Phy siol, 2004; 31:791-794. 36 Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure[J]. Circulation, 2005; 111:1487-1491. 37 Wang DJ, Dowling TC, Meadows D, et al.Nesiritide does not improve renal funct-ion in patients with chronic heart failure and worsening serum creatinine[J]. Circulation, 2004;110:1620-1625. |
[1] | HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831. |
[2] | PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183. |
[3] | CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092. |
[4] | YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015. |
[5] | PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381. |
[6] | LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218. |
[7] | XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652. |
[8] | CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97. |
[9] | FAN Jianfeng,FANG Yi,ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814. |
[10] | SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349. |
[11] | WEI Zihan,LI Dongbo,YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62. |
[12] | HUANG Ting, WANG Hegui. Research progress in regulation of heart failure by β-adrenergic-receptor-PKA-AKAP signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 592-596. |
[13] | WANG Shibiao, WANG Chengyi, WENG Bin, GUO Xiaofeng, LIN Hai. Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1402-1407. |
[14] | LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820. |
[15] | WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||